Prophylactic Application of Donor-derived TCM After Allogeneic HSCT

Myelodysplastic Syndromes Clinical Trial

— PACT  

Official title:

Prophylactic Application of Donor-derived Central Memory T Lymphocytes (TCM) After Allogeneic HSCT to Prevent Infectious Complications

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02758223
• Other study ID #: PACT2014-001
• Secondary ID: 2015-001522-41
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 2016
• Est. completion date: May 2021

Study information

• Verified date: July 2022
• Source: Wuerzburg University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PACT is a non-randomized multicentre phase I/II study to evaluate the feasibility and safety of the prophylactic administration of donor derived TCM. Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who are planned to undergo a HLA -matched (9/10 or 10/10) allogeneic hematopoietic stem cell transplantation and who are either 50+ years old or have a high comorbidity score are included according to criteria as described below. TCM will be applied in escalating doses to a maximum of 30 patients who have received T cell depleted Human leukocyte antigen (HLA)-matched alloHSCT grafts and qualify for TCM transfer.

Description:

One of the major challenges in the field of allo-SCT is to find a balance between the harmful induction of graft-versus-host disease (GVHD) and the beneficial graft-versus-leukemia (GVL) response, both mediated by donor T cells recognizing antigens expressed on cells of the recipient. Complete removal of T cells from the graft results in abrogation of severe GVHD, but is also frequently associated with removal of the immunity against infectious agents and the anti-tumor efficacy (GVT effect), which is reflected by an increased incidence of infectious complications and (early) disease relapses after T cell depleted allo-SCT. The investigators hypothesize that the prophylactic adoptive transfer of donor-derived central memory T cells is a safe and tolerable method to improve overall survival after HSCT. TCM are administered in escalating doses at day 30, day 60 and day 90 posttransplant to prevent infectious complications and early relapse or disease progression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: May 2021
• Est. primary completion date: May 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

Patient

• Male or female patients with Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score (Sorror) =3 AND/or Age 50 years or older
• Primary or secondary AML Month 0, Month 1, Month 2, Month 4, Month 5, Month 6 and Month 7, in Complete Remission (CR) (<5% blasts in bone marrow (BM)) irrespective of the cytogenetic or molecular risk profile or MDS up to Refractory anemia with excess of blasts 2 (RAEB-2) (maximal 20% blasts in bone marrow)
• Planned alloHSCT with Cluster of Differentiation 34+ (CD34+)-purified stem cell grafts after conditioning with fludarabine-melphalan-thio-thepa-ATG (ATG=Antithymocyte globulin)
• HLA-matched stem cell donor (9-10/10, maximal 1 allel- or antigen mismatch allowed) without aberrant CD45RA (=Cluster of Differentiation) expression Additional patient inclusion criteria: Treatment phase patients at day 30 +/-5 after alloHSCT: -Stable engraftment of the allogeneic graft (granulocytes > 0.5*109/L) Donor
• Donor must have met requirements of European Union (EU) Tissue and Cells Directive (2004/23/EC) (see below)
• Healthy donor - having passed medical examination for stem cell donation
• Donor must fulfill the requirements for allogeneic donor blood testing according to Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen (SC-Richtlinie (RILI) der Bundesärztekammer; 08/2014)
• Donor informed consent for the additional non-mobilized apheresis
• Written informed consent of the patient

Exclusion Criteria:

• Patient
• Disease-specific treatment foreseen in the first 6 months after alloHSCT
• Patients with AML M3
• Pregnant or lactating women
• Severe psychological disturbances
• Positive serology for Human immunodeficiency virus (HIV), Syphilis, West Nile Virus (WNV)
• Participation in another interventional clinical trial during or within 4 weeks before study entry Additional patient exclusion criteria: Treatment phase patients at day 30

+/-5 after alloHSCT:

• Disease specific treatment foreseen in the first 6 months after alloHSCT
• Acute GVHD > grade I for which immune suppressive treatment is given
• Progressive disease for which therapy is needed
• Use of > 0,5 mg/kg bw prednisone a day
• Life expectation < 12 weeks
• End stage irreversible multi-system organ failure Donor
• Donor pregnant or lactating
• Donors with aberrant CD45RA isoform expression
• General exclusion criteria for stem cell donation

Related Conditions & MeSH terms

• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes

Intervention

Biological:
• TCM allogeneic humane central memory T cells, cryopreserved
Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)

Locations

Country	Name	City	State
Germany	University Hospital Wuerzburg - Department of Medicine II	Wurzburg

Sponsors (1)

Lead Sponsor	Collaborator
Wuerzburg University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative incidence of acute GVHD > overall grade II or death	Toxicity of the infusion will be evaluated by the cumulative incidence of acute GVHD > overall grade II or death during three months after the infusion of the T cell product.	during three months after the infusion of the T cell product
Secondary	Appearance or Expansion of antigen specific T cells measured in specific T cells per mikroliter	the determination of appearance or expansion of antigen specific T cells (measured in specific T cells per mikroliter) from donor derived TCM during 36 weeks (9 months) after the first infusion of study medication.	during 9 months after first infusion
Secondary	Clinical signs of viral infections - fever in °celsius	Clinical signs of viral infections - fever in °celsius	During 10 months after first application until study end (per patient)
Secondary	Incidence of relapse		During 10 months after first application until study end (per patient)
Secondary	Incidence of bacterial and fungal infections		During 10 months after first application until study end (per patient)
Secondary	Incidence of GvHD grade II-IV		During 10 months after first application until study end (per patient)
Secondary	Donor chimerism in bone marrow and peripheral blood measured in % of nucleated cells		During 10 months after first application until study end (per patient)
Secondary	Incidence of viremia and clinical manifestations of virus-related organ manifestations (Cytomegalovirus (CMV), Eppstein-Barr virus (EBV), Adenovirus, Herpes Simplex Virus (HSV), Varicella-Zoster Virus (VZV))		During 10 months after first application until study end (per patient)
Secondary	quantification of CMV specific T cells by multimer staining and ics (copies / ml)	Efficacy of the transfer of TCM will be evaluated by quantification of CMV specific T cells by multimer staining and ics before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer.	before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer.
Secondary	quantification of EBV specific T cells by multimer staining and ics (copies / ml)	Efficacy of the transfer of TCM will be evaluated by quantification of EBV specific T cells by multimer staining and ics before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer.	before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer.
Secondary	quantification of Adenovirus specific T cells by multimer staining and ics (copies / ml)	Efficacy of the transfer of TCM will be evaluated by quantification of Adenovirus specific T cells by multimer staining and ics before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer.	before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer.